A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National ...

Sofetabart mipitecan (LY4170156), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), elicited strong antitumor activity in patients with recurrent ...

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers: London, UK Tuesday, April 14, 2026, 13:00 Hrs [IST] GSK plc announced positive findings from its globa ...

EMA recommends marketing authorisation in EU for Imdylltra to treat adults with extensive-stage small cell lung cancer: Amsterdam, The Netherlands Monday, March 30, 2026, 17:00 Hr ...

Dr. Alexander B. Olawaiye presented findings at the 2026 Society of Gynecologic Oncology Annual Meeting showing that adding ...

The American Society of Hematology (ASH) released guidelines on the diagnosis and management of severe acquired aplastic anemia, a rare and ...

The DPP1 inhibitor did not beat placebo in this trial, leaving branded Bimzelx and Cosentyx, as well as Humira and its generics to reign across the HS market.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with ...

Feeling tired all the time isn’t just frustrating—it may be your body signaling that something deeper needs attention.

A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).

During perimenopause and menopause, fluctuations in estrogen and progesterone can make the body’s stress response more ...